Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6027 |
Delanzomib
德兰佐米,CEP-18770 |
Apoptosis; NF-κB; Proteasome | Apoptosis; NF-κB; Proteases/Proteasome; Ubiquitination |
Delanzomib (CEP-18770) 是一种强效的具有口服活性的蛋白酶体的胰凝乳蛋白酶样活性抑制剂,IC50为 3.8 nM。它抑制NF-κB 活性,诱导癌细胞凋亡,具有很强的抗血管生成和抗癌活性。 | |||
T69288 |
CEP-7055
|
||
CEP-18770 is an orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cel... |